Meiting Chen

Key Laboratory For Prevention And Control Of Avian Influenza And Other Major Poultry Diseases, Scientific Observation And Experiment Station Of Veterinary Drugs And Diagnostic Techniques Of Guangdong Province
Guangzhou, 510640, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 42 publications

A novel Chaphamaparvovirus detected in breeding Muscovy Ducks with hepatitis.

A novel Chaphamaparvovirus detected in breeding Muscovy Ducks with hepatitis.

Journal: Veterinary research communications

Published: January 25, 2026

Camrelizumab Plus Nab-paclitaxel in Patients with Previously Treated Advanced Urothelial Carcinoma: A Multicenter Phase II Study.

Camrelizumab Plus Nab-paclitaxel in Patients with Previously Treated Advanced Urothelial Carcinoma: A Multicenter Phase II Study.

Journal: Cancer communications (London, England)

Published: December 13, 2025

Germline Pathogenic Variants in HER2-Positive Breast Cancer: Spectrum and Clinical Implications in a High-Risk Chinese Cohort.

Germline Pathogenic Variants in HER2-Positive Breast Cancer: Spectrum and Clinical Implications in a High-Risk Chinese Cohort.

Journal: Cancer medicine

Published: August 30, 2025

Estradiol levels in women with hormone receptor-positive advanced breast cancer on fulvestrant therapy.

Estradiol levels in women with hormone receptor-positive advanced breast cancer on fulvestrant therapy.

Journal: The oncologist

Published: July 14, 2025

Prognostic index for predicting outcomes of trastuzumab deruxtecan in HER2 expressing metastatic breast cancer: a real-world multicenter study.

Prognostic index for predicting outcomes of trastuzumab deruxtecan in HER2 expressing metastatic breast cancer: a real-world multicenter study.

Journal: The oncologist

Published: April 16, 2025

Tumor microenvironment-responsive nanoparticles composed of hyaluronic acid and stearic acid for the treatment of lung metastasis in triple-negative breast cancer.

Tumor microenvironment-responsive nanoparticles composed of hyaluronic acid and stearic acid for the treatment of lung metastasis in triple-negative breast cancer.

Journal: International journal of biological macromolecules

Published: April 13, 2025

Bevacizumab, tislelizumab and nab-paclitaxel for previously untreated metastatic triple-negative breast cancer: a phase II trial.

Bevacizumab, tislelizumab and nab-paclitaxel for previously untreated metastatic triple-negative breast cancer: a phase II trial.

Journal: Journal for immunotherapy of cancer

Published: March 24, 2025

Osteosclerotic changes on computed tomography predict disease progression and poor survival in prostate cancer with osteoblastic metastases.

Osteosclerotic changes on computed tomography predict disease progression and poor survival in prostate cancer with osteoblastic metastases.

Journal: International journal of surgery (London, England)

Published: March 23, 2025

Clinical outcome and genomic biomarkers of immune checkpoint inhibitor-based therapies for cancer of unknown primary: a multicenter, real-world study.

Clinical outcome and genomic biomarkers of immune checkpoint inhibitor-based therapies for cancer of unknown primary: a multicenter, real-world study.

Journal: Journal of cancer research and clinical oncology

Published: March 20, 2025

Trastuzumab Deruxtecan in Low or Ultralow HER2 Metastatic Breast Cancer.

Trastuzumab Deruxtecan in Low or Ultralow HER2 Metastatic Breast Cancer.

Journal: The New England journal of medicine

Published: February 19, 2025

RC48-ADC monotherapy or in combination with immunotherapy for locally advanced or metastatic urothelial carcinoma with HER2 low and null expression: a multicenter, real-world, retrospective study.

RC48-ADC monotherapy or in combination with immunotherapy for locally advanced or metastatic urothelial carcinoma with HER2 low and null expression: a multicenter, real-world, retrospective study.

Journal: BMC cancer

Published: February 05, 2025

Olanzapine combined with standard antiemetics for the prevention of nausea and vomiting in patients with germ cell tumor undergoing a 5-day cisplatin-based chemotherapy (NAVIGATE study)： A phase III crossover trial.

Olanzapine combined with standard antiemetics for the prevention of nausea and vomiting in patients with germ cell tumor undergoing a 5-day cisplatin-based chemotherapy (NAVIGATE study)： A phase III crossover trial.

Journal: European journal of cancer (Oxford, England : 1990)

Published: January 07, 2025

Showing 1-12 of 42

Last Updated: 09/26/2026